Evidence map›Paper›PMID 29966518›Full record

ArticleCell communication and signaling : CCS2018

Inhibition of integrin α

P Olof Olsson, Renata Gustafsson, Alexei V Salnikov, Maria Göthe, Kathrin S Zeller, Tomas Friman, Bo Baldetorp, Louise A Koopman, Paul H Weinreb, Shelia M Violette and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cell communication and signaling : CCS, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Integrin Alpha v Beta 6 (αvβ6) and Its Implications in Cancer Treatment.International journal of molecular sciences · 2022
    Review
  7. Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

P Olof OlssonDepartment of Experimental Medical Science, Medicon Village 406, SE-22381, Lund, Sweden.
Renata GustafssonDepartment of Experimental Medical Science, Medicon Village 406, SE-22381, Lund, Sweden.
Alexei V SalnikovOncology Clinic, Department of Clinical Sciences, University Hospital Lund, SE-221 85, Lund, Sweden.
Maria GötheScience for Life Laboratories, Department of Medical Biochemistry and Microbiology, Uppsala University, BMC, Box 582, SE-751 23, Uppsala, Sweden.
Kathrin S ZellerScience for Life Laboratories, Department of Medical Biochemistry and Microbiology, Uppsala University, BMC, Box 582, SE-751 23, Uppsala, Sweden.
Tomas FrimanScience for Life Laboratories, Department of Medical Biochemistry and Microbiology, Uppsala University, BMC, Box 582, SE-751 23, Uppsala, Sweden.
Bo BaldetorpOncology Clinic, Department of Clinical Sciences, University Hospital Lund, SE-221 85, Lund, Sweden.
Louise A KoopmanBiogen, 225 Binney Street, Cambridge, MA, 02142, USA.
Paul H WeinrebBiogen, 225 Binney Street, Cambridge, MA, 02142, USA.
Shelia M VioletteBiogen, 225 Binney Street, Cambridge, MA, 02142, USA.
Sebastian KalamajskiScience for Life Laboratories, Department of Medical Biochemistry and Microbiology, Uppsala University, BMC, Box 582, SE-751 23, Uppsala, Sweden.
Nils-Erik HeldinDepartment of Immunology, Genetics and Pathology, The Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.
Kristofer RubinScience for Life Laboratories, Department of Medical Biochemistry and Microbiology, Uppsala University, BMC, Box 582, SE-751 23, Uppsala, Sweden. Kristofer.Rubin@imbim.uu.se.ORCID 0000-0003-2789-6276
Uppsala University · SEBiogen (United States) · USLund University · SEMedicon Village · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChemotherapeutic efficacy can be improved by targeting the structure and function of the extracellular matrix (ECM) in the carcinomal stroma. This can be accomplished by e.g. inhibiting TGF-β1 and -β3 or treating with Imatinib, which results in scarcer collagen fibril structure in xenografted human KAT-4/HT29 (KAT-4) colon adenocarcinoma.

methodsThe potential role of α

resultsBoth KAT-4 and Capan-2 cells expressed the α

conclusionOur data demonstrate that the α

Indexed as

AnimalsAntibodies, MonoclonalAntigens, NeoplasmCell Line, TumorCell Transformation, NeoplasticCollagenExtracellular FluidFemaleGene Expression ProfilingHumansIntegrinsMicePressureTransforming Growth Factor betaAntibodies, MonoclonalAntigens, NeoplasmCollagenintegrin alphavbeta6IntegrinsTransforming Growth Factor beta

Identifiers

PMID29966518
PMCPMC6027735
OpenAlexW2810682043

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.